openPR Logo
Press release

Liver Cancer Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies Involved

08-17-2022 07:18 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Liver Cancer Therapeutic Pipeline

Liver Cancer Therapeutic Pipeline

As per DelveInsight's assessment, globally, nearly 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Liver Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development expected to launch in the coming years.

"Liver Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Liver Cancer Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Download the sample pages:
https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Liver Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights about companies that are developing therapies in the Liver Cancer • Market.
• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cancer treatment.
• Liver Cancer key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liver Cancer Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF:
https://www.delveinsight.com/report-store/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Liver Cancer Therapeutics Analysis
There are approx. 75+ key companies which are developing therapies for Liver Cancer. Polaris Group has its Liver Cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Liver Cancer Market include:
• Shanghai Henlius Biotech
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Jiangsu Hengrui Medicine
• GlaxoSmithKline
• ZAI Lab
• Beijing Immunochina Medical Science and Technology
• MiNA Therapeutics
• Abbisko Therapeutics
• Medivir AB
• Teclison
• Genoscience
• Eureka Therapeutics
• Celsion Corporation
• H3 Biomedicine
• TriSalus Life Sciences
• Celldex Therapeutics
• Takeda
• Megapro Biomedical Company
• Polaris Group
And many more

Liver Cancer Therapies covered in the report include:
• SRF388 (Surface Oncology)
• MTL-CEBPA (MiNA Therapeutics)
• APX3330 (Ocuphire Pharma)
• Fostroxacitabine bralpamide (Medivir)
• CDX-527 (Celldex Therapeutics)
And many more

Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Liver Cancer Current Treatment Patterns
4. Liver Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Liver Cancer Late Stage Products (Phase-III)
7. Liver Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Liver Cancer Discontinued Products
13. Liver Cancer Product Profiles
14. Liver Cancer Key Companies
15. Liver Cancer Key Products
16. Dormant and Discontinued Products
17. Liver Cancer Unmet Needs
18. Liver Cancer Future Perspectives
19. Liver Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at:
https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/liver-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Liver Cancer Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies Involved here

News-ID: 2706524 • Views:

More Releases from DelveInsight Business Research

Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight
Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinic …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rheumatoid Arthritis pipeline constitutes 75+ key companies continuously working towards developing 80+ Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Rheumatoid Arthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market. The Rheumatoid
Ulcerative Colitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates
Ulcerative Colitis Market Insights Highlight Expanding Outlook Till 2034, DelveI …
DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of
Global Biologics Drug Substance Manufacturing Market to grow at a CAGR of 10.59% to reach USD 968.32 billion by 2032, Evaluates DelveInsight
Global Biologics Drug Substance Manufacturing Market to grow at a CAGR of 10.59% …
According to DelveInsight's analysis, The biologics drug substance manufacturing market is witnessing robust growth, largely driven by the rising prevalence of chronic diseases, which is increasing the demand for biologics development and production. Contributing factors include technological advancements in manufacturing processes, heightened R&D activities, and a surge in product launches by leading industry players. Additionally, the growing adoption of biologic therapies is further supporting market expansion. These elements are expected
Global Fetal & Neonatal Care Equipment Market to grow at a CAGR of 8.33% to reach USD 15,616.87 million by 2032, Evaluates DelveInsight
Global Fetal & Neonatal Care Equipment Market to grow at a CAGR of 8.33% to reac …
According to DelveInsight's analysis, The global demand for fetal and neonatal care equipment is largely driven by the rising incidence of preterm births. Additionally, the growing prevalence of congenital anomalies and birth defects, coupled with ongoing technological advancements, is supporting market growth. Continuous product innovations and frequent launches by key players are also contributing to the expansion of the market. These factors are expected to play a crucial role in

All 5 Releases


More Releases for Liver

Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Liver Metastases Treatment Market Size By 2025? The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health. ● Product Name - LivCare
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production